DIFFERENT METABOLIC AND CLINICAL PROFILES BETWEEN PATIENTS WITH PURE ALZHEIMER DEMENTIA AND EPILEPTIC ALZHEIMER DEMENTIA : A METABOLIC STUDY

Aim: To investigate the clinical characteristics and cerebral FDG PET metabolisms of dementia patients who also diagnosed with epilepsy and compare the differences between with the pure Alzheimer dementia patients. 
Methods: In this case-control study, a total of 14 patients; 7 patients with pure Alzheimer disease as a control group and 7 age and gender matched patients with Alzheimer disease and concomitant epilepsy as a study group were included. Detailed neurocognitive battery and brain fludeoxyglucose positron emission tomography (FDG PET-CT) were performed for all subjects. 
Results: In comparison of neurocognitive test scores, there was no significant difference between study and control groups. However, geriatric depression scale scores were significantly lower in study group than the controls (p= 0.026). In cerebral FDG-PET CT profiles of subjects we detected significantly lower metabolism in left and right cerebellum, left lentiform nucleus, right thalamus and vermis in the study group (p=0.008, p=0.023, p=0.003, p=0.002, p=0.002, respectively). In the right parietotemporal cortex and right and left associative visual cortex, we found higher metabolism in the study group than controls ( p=0.023, p=0.012, p=0.003, respectively). 
Conclusion: Epileptic patients with Alzheimer dementia may have distinct clinical and metabolic profile than pure Alzheimer disease patients. Even if there is no difference in the neurocognitive clinical scores of the patients, depression and related functional abnormalities may be a biomarker of epileptic AD.